Semax and Neuroplasticity in Preclinical Models

Semax is a synthetic heptapeptide developed from the adrenocorticotropic hormone (ACTH) sequence. It was designed to retain neuropeptide activity while eliminating endocrine effects and has been studied extensively in Russian and international research literature for its neuroactive properties.

Mechanisms of Action

Semax has been investigated in preclinical models for its effects on neuroplasticity markers, brain-derived neurotrophic factor (BDNF) expression, and monoaminergic systems including dopamine and serotonin. Studies have also explored its neuroprotective properties in models of cerebral ischemia and its effects on gene expression related to synaptic plasticity and neural adaptation.

*For laboratory and research purposes only. Not for human or animal consumption.*

Disclaimer: The information provided in this article is for educational and informational purposes only. All compounds discussed are for laboratory and research purposes only. Not for human or animal consumption. No medical claims are made.